Published by Benjamin Chiou on 17th April 2025
(Sharecast News) - Shares in Eli Lilly & Co were set to soar on Wednesday on the back of positive results of a late-stage trial of its weight-loss pill Orforglipron, which is thought to be a needle-free alternative to Novo Nordisk's popular injectable Ozempic drug.
URL: http://www.digitallook.com/dl/news/story/35021849/...